[HTML][HTML] Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection
The outbreak of 2019-novel coronavirus disease (COVID-19), caused by SARS-CoV-2,
started in late 2019; in a short time, it has spread rapidly all over the world. Although some …
started in late 2019; in a short time, it has spread rapidly all over the world. Although some …
Coronaviruses—drug discovery and therapeutic options
In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43,
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
The spike protein of SARS-CoV—a target for vaccine and therapeutic development
L Du, Y He, Y Zhou, S Liu, BJ Zheng… - Nature Reviews …, 2009 - nature.com
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused
by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is …
by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is …
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Background First vaccines for prevention of Coronavirus disease 2019 (COVID‐19) are
becoming available but there is a huge and unmet need for specific forms of treatment. In …
becoming available but there is a huge and unmet need for specific forms of treatment. In …
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
MJ Vincent, E Bergeron, S Benjannet, BR Erickson… - Virology journal, 2005 - Springer
Background Severe acute respiratory syndrome (SARS) is caused by a newly discovered
coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently …
coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently …
Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
J Dyall, R Gross, J Kindrachuk, RF Johnson… - Drugs, 2017 - Springer
No specific antivirals are currently available for two emerging infectious diseases, Middle
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
VCC Cheng, SKP Lau, PCY Woo… - Clinical microbiology …, 2007 - Am Soc Microbiol
Before the emergence of severe acute respiratory syndrome (SARS) coronavirus (SARS-
CoV) in 2003, only 12 other animal or human coronaviruses were known. The discovery of …
CoV) in 2003, only 12 other animal or human coronaviruses were known. The discovery of …
Severe acute respiratory syndrome
JSM Peiris, Y Guan, KY Yuen - Nature medicine, 2004 - nature.com
Severe acute respiratory syndrome (SARS) was caused by a previously unrecognized
animal coronavirus that exploited opportunities provided by'wet markets' in southern China …
animal coronavirus that exploited opportunities provided by'wet markets' in southern China …
The epigenetic implication in coronavirus infection and therapy
S Atlante, A Mongelli, V Barbi, F Martelli, A Farsetti… - Clinical …, 2020 - Springer
Epigenetics is a relatively new field of science that studies the genetic and non-genetic
aspects related to heritable phenotypic changes, frequently caused by environmental and …
aspects related to heritable phenotypic changes, frequently caused by environmental and …
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
B Li, Q Tang, D Cheng, C Qin, FY Xie, Q Wei, J Xu… - Nature medicine, 2005 - nature.com
Abstract Development of therapeutic agents for severe acute respiratory syndrome (SARS)
viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new …
viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new …